Promyelocytic leukemia-retinoic acid receptor alpha-silencing mediator for retinoid and thyroid hormone receptors corepressor complex (PML-RARα-SMRT complex)

The Promyelocytic leukemia-retinoic acid receptor alpha-silencing mediator for retinoid and thyroid hormone receptors (PML-RARα–SMRT) corepressor complex is a pathological molecular assembly central to the pathogenesis of acute promyelocytic leukemia (APL) (Lin et al., 1998, Nature). It forms when the PML-RARα fusion protein, resulting from the t(15;17) chromosomal translocation, recruits the SMRT (NCOR2) corepressor and associated histone deacetylases (HDACs) to retinoic acid response elements in the genome (Grignani et al., 1998, Nature). This recruitment leads to constitutive transcriptional repression of genes essential for myeloid differentiation, effectively halting granulocyte maturation at the promyelocytic stage (He et al., 1998, Nature Genetics). Unlike the wild-type RARα, the fusion protein binds SMRT with significantly higher affinity, requiring supra-physiological concentrations of retinoic acid to trigger corepressor release (Guidez et al., 1998, Blood). Therapeutic intervention with all-trans retinoic acid (ATRA) induces a conformational change that facilitates the dissociation of SMRT and the recruitment of coactivators, thereby restoring gene expression (Zhou et al., 2006, Nature). Arsenic trioxide further complements this by binding directly to the PML moiety, inducing the degradation of the PML-RARα protein via the ubiquitin-proteasome pathway (Zhang et al., 2010, Science). This dual approach effectively dismantles the repressive complex, allowing leukemic cells to undergo terminal differentiation and clinical remission (Lallemand-Breitenbach et al., 2008, Nature Reviews Cancer).

Other names

PML-RARA-NCOR2 complexPML-RARalpha-SMRT complexPML-RARα-HDAC-SMRT complexPML-RARα-N-CoR/SMRT complexPML-RARα-SMRT-HDAC3 complex

Ligand-induced dissociation of the SMRT corepressor complex from the PML-RARα fusion protein; Recruitment of transcriptional coactivators (e.g., p300/CBP) to restore gene expression; Proteasomal degradation of the PML-RARα oncoprotein; Induction of terminal myeloid differentiation and apoptosis.